2,543 Shares in Johnson & Johnson (NYSE:JNJ) Acquired by CVA Family Office LLC

CVA Family Office LLC bought a new position in shares of Johnson & Johnson (NYSE:JNJ) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 2,543 shares of the company’s stock, valued at approximately $371,000.

A number of other large investors also recently added to or reduced their stakes in the business. Bank of New York Mellon Corp grew its position in Johnson & Johnson by 3.2% during the 4th quarter. Bank of New York Mellon Corp now owns 32,846,195 shares of the company’s stock worth $4,791,274,000 after purchasing an additional 1,021,877 shares during the last quarter. Massachusetts Financial Services Co. MA grew its position in Johnson & Johnson by 3.5% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 27,407,188 shares of the company’s stock worth $3,997,886,000 after purchasing an additional 915,066 shares during the last quarter. FMR LLC grew its position in Johnson & Johnson by 4.7% during the 4th quarter. FMR LLC now owns 17,945,766 shares of the company’s stock worth $2,617,750,000 after purchasing an additional 799,194 shares during the last quarter. Franklin Resources Inc. grew its position in Johnson & Johnson by 11.6% during the 4th quarter. Franklin Resources Inc. now owns 12,626,462 shares of the company’s stock worth $1,841,810,000 after purchasing an additional 1,311,739 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its position in Johnson & Johnson by 0.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 12,347,039 shares of the company’s stock worth $1,801,063,000 after purchasing an additional 88,125 shares during the last quarter. 69.30% of the stock is currently owned by institutional investors.

In related news, COO Michael E. Sneed sold 58,128 shares of the stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $149.39, for a total transaction of $8,683,741.92. Following the sale, the chief operating officer now directly owns 107,511 shares of the company’s stock, valued at $16,061,068.29. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director William D. Perez purchased 500 shares of the stock in a transaction that occurred on Friday, March 13th. The shares were purchased at an average cost of $127.69 per share, for a total transaction of $63,845.00. Following the completion of the acquisition, the director now directly owns 16,030 shares of the company’s stock, valued at approximately $2,046,870.70. The disclosure for this purchase can be found here. Corporate insiders own 0.27% of the company’s stock.

Several analysts have weighed in on the stock. Barclays raised shares of Johnson & Johnson from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $140.00 to $173.00 in a research report on Thursday, December 19th. Zacks Investment Research raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $158.00 price objective on the stock in a report on Wednesday, December 18th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $168.00 price objective on shares of Johnson & Johnson in a report on Thursday, January 23rd. Wells Fargo & Co upped their price objective on shares of Johnson & Johnson from $155.00 to $165.00 and gave the company an “overweight” rating in a report on Thursday, January 9th. Finally, Morgan Stanley raised shares of Johnson & Johnson from an “equal weight” rating to an “overweight” rating and upped their price objective for the company from $145.00 to $170.00 in a report on Tuesday, December 17th. Two research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $162.33.

NYSE JNJ traded up $3.24 during mid-day trading on Wednesday, reaching $122.42. 7,032,822 shares of the stock were exchanged, compared to its average volume of 15,632,667. The business’s 50 day moving average is $141.31 and its 200-day moving average is $138.39. Johnson & Johnson has a 1 year low of $109.16 and a 1 year high of $154.50. The company has a market capitalization of $293.00 billion, a P/E ratio of 18.06, a P/E/G ratio of 1.85 and a beta of 0.74. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.01 and a current ratio of 1.26.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, January 22nd. The company reported $1.88 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.87 by $0.01. Johnson & Johnson had a net margin of 22.18% and a return on equity of 39.27%. The firm had revenue of $20.75 billion for the quarter, compared to the consensus estimate of $20.83 billion. During the same period in the prior year, the firm posted $1.97 earnings per share. The firm’s quarterly revenue was up 1.7% compared to the same quarter last year. Equities analysts predict that Johnson & Johnson will post 9.03 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which was paid on Tuesday, March 10th. Investors of record on Tuesday, February 25th were issued a dividend of $0.95 per share. This represents a $3.80 dividend on an annualized basis and a yield of 3.10%. The ex-dividend date was Monday, February 24th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 43.78%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Read More: Why are percentage decliners important?

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.